Fundraising FoxDecoy Therapeutics
NASDAQ: DCOYCambridge, US · Delaware corporation
Find your way into Decoy Therapeutics
Sign up to see every warm intro you have to Decoy Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Decoy Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Decoy Therapeutics is a pre-clinical stage biotechnology company developing peptide conjugate therapeutics using its proprietary IMP³ACT platform, which combines machine learning and artificial intelligence with high-speed synthesis to engineer treatments targeting infectious diseases and oncology.
Founders & leadership
BH
Barbara HibnerExecutive
ML
Michael LippExecutiveMichael Lipp joined Decoy Therapeutics as Chief Technology Officer in July 2023, bringing over 20 years of experience in pharmaceutical development and drug delivery across preclinical and commercial stages. He previously held senior roles at Nocion Therapeutics, Civitas/Acorda Therapeutics (where he led CMC activities for FDA-approved Inbrija), Pulmatrix, and Alkermes, and holds degrees in chemical engineering from Cornell University and UC Santa Barbara, plus a NIH postdoctoral fellowship from MIT in the lab of Robert Langer.
FE
Frederick Ernest PierceNamed on SEC filing
PK
Peter Klaus MarschelNamed on SEC filing
Funding
SEC filings, press & company announcements$1.2M disclosed across 1 of 2 rounds · 2025–2026
- Undisclosed amountPIPEJun 2026Source ↗
▶$1.2MraisedJul 2025 · 20 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedJul 2025 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Barbara HibnerExecutive Officer, Director
- Frederick Ernest PierceExecutive Officer, Director
- Michael LippExecutive Officer
- Peter Klaus MarschelExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- Sales commissions
- $150K
- Placement agents
- Craft Capital Management LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Decoy Therapeutics do?
- Decoy Therapeutics is a pre-clinical stage biotechnology company developing peptide conjugate therapeutics using its proprietary IMP³ACT platform, which combines machine learning and artificial intelligence with high-speed synthesis to engineer treatments targeting infectious diseases and oncology.
- How much funding has Decoy Therapeutics raised?
- Decoy Therapeutics has disclosed $1.2M raised across 1 of its 2 known rounds.
- Where is Decoy Therapeutics headquartered?
- Decoy Therapeutics is headquartered in Cambridge, US.